Saralasin is an angiotensin II analogue which was developed for the treatment of hypertension in 1970s. For many years saralasin was supposed to be angiotensin receptors blocker, but recent studies have revealed that its pharmacological action can be explained by agonistic behavior toward angiotensin II receptor. The drug was approved by FDA under the name Sarenin, however, it is no longer available on the market.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094256 |
0.38 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: DOI: 10.1007/978-1-4613-3822-2 J. Strauss, Acute Renal Disorders and Renal Emergencies (1984), page 164, retrieved from: https://books.google.es/books?id=B_QGCAAAQBAJ&dq |
Primary | SARENIN Approved UseUnknown Launch Date1981 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. | 2003 Nov 15 |
|
| Stimulation of NHE3 in OKP cells by an autocrine mechanism. | 2004 |
|
| Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anaesthetized dogs. | 2004 Aug |
|
| Angiotensin II receptor blockade inhibits pneumocyte apoptosis in experimental meconium aspiration. | 2004 Feb |
|
| Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. | 2004 Jun 25 |
|
| Pharmacological properties of angiotensin II receptors in cultured rabbit gingival fibroblasts. | 2004 Mar |
|
| Intracoronary angiotensin II causes inotropic and vascular effects via different paracrine mechanisms. | 2004 May-Jun |
|
| A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception. | 2005 |
|
| Angiotensin II receptor inhibition prevents pneumocyte apoptosis in surfactant-depleted rat lungs. | 2005 Apr |
|
| Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. | 2005 Aug 22 |
|
| Inhibition of angiotensin II- and endothelin-1-stimulated proliferation by selective MEK inhibitor in cultured rabbit gingival fibroblastsdagger. | 2005 Dec |
|
| Angiotensin II and III upregulate body fluid volume of the clam worm Perinereis sp. via angiotensin II receptors in different manners. | 2005 Dec |
|
| Angiotensin II inhibition of Ca2+ currents is independent of ATR1 angiotensin II receptor activation in rat adult vagal afferent neurons. | 2005 Feb 7 |
|
| Antiproliferative action of an angiotensin I-converting enzyme inhibitory peptide, Val-Tyr, via an L-type Ca2+ channel inhibition in cultured vascular smooth muscle cells. | 2005 Jun |
|
| Angiotensin II reverses the inhibitory action produced by theca cells on bovine oocyte nuclear maturation. | 2005 Mar 1 |
|
| Memory strengthening by a real-life episode during reconsolidation: an outcome of water deprivation via brain angiotensin II. | 2005 Oct |
|
| Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1. | 2006 |
|
| Regulation of cGMP synthesis in cultured podocytes by vasoactive hormones. | 2006 Dec |
|
| Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. | 2006 Feb |
|
| Analysis of the mechanisms underlying the vasorelaxant action of angiotensin II in the isolated rat carotid. | 2006 May 1 |
|
| A non-radioactive method for angiotensin II receptor binding studies using the rat liver. | 2006 May-Jun |
|
| Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. | 2006 Sep 6 |
|
| Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. | 2007 |
|
| Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. | 2007 |
|
| Role of the brain renin-angiotensin system in blood pressure regulation. | 2007 Aug |
|
| Cardiovascular effects of centrally injected melittin in hemorrhaged hypotensive rats: the investigation of peripheral mechanisms. | 2007 Dec |
|
| Stretch-induced alveolar type II cell apoptosis: role of endogenous bradykinin and PI3K-Akt signaling. | 2007 Dec |
|
| Role of the AT1A receptor in the CO2-induced stimulation of HCO3- reabsorption by renal proximal tubules. | 2007 Jul |
|
| Cardiovascular response to renin substrate microinjection into the central nucleus of the amygdala of rats. | 2007 May 7 |
|
| The role of angiotensin II in the early stages of bovine ovulation. | 2007 Nov |
|
| Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells. | 2007 Nov 5 |
|
| Interaction between endothelin and angiotensin II in the up-regulation of vasopressin messenger RNA in the inner medullary collecting duct of the rat. | 2007 Oct |
|
| The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis? | 2008 |
|
| Importance and limits of ischemia in renal partial surgery: experimental and clinical research. | 2008 |
|
| Physiological effects of complexes of angiotensins with functionally different carrier proteins. | 2008 Aug |
|
| Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. | 2008 Dec |
|
| Evidence that the effect of angiotensin II on bovine oocyte nuclear maturation is mediated by prostaglandins E2 and F2alpha. | 2008 Dec |
|
| Angiotensin II- and glucose-stimulated extracellular matrix production: mediation by the insulin-like growth factor (IGF) axis in a murine mesangial cell line. | 2008 Feb |
|
| Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. | 2008 Jul |
|
| Peripheral mechanisms involved in the pressor and bradycardic effects of centrally administered arachidonic acid. | 2008 Jun |
|
| Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. | 2008 Oct |
|
| Angiotensin II and myosin light-chain phosphorylation contribute to the stretch-induced slow force response in human atrial myocardium. | 2008 Sep 1 |
|
| Angiotensin II type 1 receptor blockade: high hopes sent back to reality? | 2009 Dec |
|
| Angiotensin II induces apoptosis in human mural granulosa-lutein cells, but not in cumulus cells. | 2009 May |
|
| Two dissimilar AT(1) agonists distinctively activate AT(1) receptors located on the luminal membrane of coronary endothelium. | 2009 Nov-Dec |
|
| Paraquat increases connective tissue growth factor and collagen expression via angiotensin signaling pathway in human lung fibroblasts. | 2010 Apr |
|
| Brain renin-angiotensin system modifies the blood pressure response to intracerebroventricular cadmium in rats. | 2010 Jul |
|
| Determinants of CREB degradation and KChIP2 gene transcription in cardiac memory. | 2010 Jul |
|
| Angiotensin modulates long-term memory expression but not long-term memory storage in the crab Chasmagnathus. | 2010 Nov |
|
| Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study. | 2010 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: DOI 10.1007/978-1-4613-3822-2, J. Strauss, Acute Renal Disorders and Renal Emergencies (1984), p. 164, Retrieved from https://books.google.es/books?id=B_QGCAAAQBAJ&dq
The recommended dose is 0.05-15 ug/kg/min given as continous IV infusion by pump.
Route of Administration:
Intravenous
| Substance Class |
Protein
Created
by
admin
on
Edited
Fri Dec 15 16:33:04 GMT 2023
by
admin
on
Fri Dec 15 16:33:04 GMT 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
H2AFV2HE66
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SARALASIN
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
m9779
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
34273-10-4
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
H2AFV2HE66
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
C66527
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
SUB10447MIG
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
DB06763
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL938
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
D012504
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
3484
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | |||
|
9556
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY | RxNorm | ||
|
3542
Created by
admin on Fri Dec 15 16:33:04 GMT 2023 , Edited by admin on Fri Dec 15 16:33:04 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Bingding Assay
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|